BMS-906024

Last updated
BMS-906024
BMS-906024.svg
Identifiers
  • (2R,3S)-N-[(3S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)succinamide
CAS Number
PubChem CID
PubChemSID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C26H26F6N4O3
Molar mass 556.509 g·mol−1
3D model (JSmol)
  • CN1c2ccccc2C(=N[C@@H](C1=O)NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(=O)N)c3ccccc3
  • InChI=1S/C26H26F6N4O3/c1-36-19-10-6-5-9-18(19)20(15-7-3-2-4-8-15)34-22(24(36)39)35-23(38)17(12-14-26(30,31)32)16(21(33)37)11-13-25(27,28)29/h2-10,16-17,22H,11-14H2,1H3,(H2,33,37)(H,35,38)/t16-,17+,22+/m0/s1
  • Key:AYOUDDAETNMCBW-GSHUGGBRSA-N

BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, colon cancers and leukemia. [1] The drug works as a pan-Notch inhibitor. The structure is one of a set patented in 2012, [2] and is being studied in clinical trials. [3] [4] [5]

References

  1. ↑ Drahl C (2013). "Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA". Chemical and Engineering News. American Chemical Society.
  2. ↑ WO 2012129353,Quesnelle C, Kim SH, Lee F, Gavai A,"Bisfluoroalkyl-1,4-Benzodiazepinone Compounds",published 27 September 2012, assigned to Bristol-Myers Squibb Company
  3. ↑ Gavai AV, Quesnelle C, Norris D, Han WC, Gill P, Shan W, et al. (May 2015). "Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors". ACS Medicinal Chemistry Letters. 6 (5): 523–7. doi:10.1021/acsmedchemlett.5b00001. PMC   4434460 . PMID   26005526.
  4. ↑ Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, et al. (December 2017). "Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma". Molecular Cancer Therapeutics. 16 (12): 2759–2769. doi:10.1158/1535-7163.MCT-17-0439. PMC   5716926 . PMID   28978720.
  5. ↑ Sosa Iglesias V, Theys J, Groot AJ, Barbeau LM, Lemmens A, Yaromina A, et al. (2018). "Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells". Frontiers in Oncology. 8: 460. doi: 10.3389/fonc.2018.00460 . PMC   6234899 . PMID   30464927.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.